New York, New York (PRWEB) January 25, 2014
Product liability claims alleging, among other things, an association between diabetes drugs like Byetta and pancreatic cancer (http://www.byettalawsuit.com/byetta-pancreatic-cancer/) continue to move forward in state and federal courts around the country, Bernstein Liebhard LLP reports. According to court documents, a joint status conference was convened last week in the federal and state incretin mimetics litigations currently underway in California. According to an Order issued on January 17, 2014 in the U.S. District Court, Southern District of California, the two proceedings are being coordinated. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
The Order also noted that there are now 35 Byetta lawsuits pending in the federal multidistrict litigation that allege use of the drug caused plaintiffs to suffer thyroid cancer. According to the document, a Byetta lawsuit involving pancreatitis allegations is scheduled to go to trial in California Superior Court on February 18, 2014. (In re: Byetta Cases, JCCP No. 4574)
“We have heard from a number of Byetta users who are concerned that the use of this diabetes drug resulted in their diagnosis of pancreatic cancer, pancreatitis or thyroid cancer. We are pleased to see these cases proceeding, and look forward to the start of the first trial in the state litigation next month,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.
Byetta and Pancreatic Cancer
According to court documents, at least 262 product liability lawsuits have been filed against the makers of incretin mimetics, including Byetta, Januvia and Victoza, in the federal multidistrict litigation underway in the Southern District of California. These lawsuits began to mount in March 2013, after the U.S. Food & Drug Administration (FDA) launched an investigation of their potential association with pancreatic cancer. The FDA embarked on its investigation after a small study found drugs like Byetta might cause precancerous changes to the cells of the pancreas. Though the FDA has so far been unable to conclude that such an association does exist, its review is ongoing.
The Institute for Safe Medicine Practices reported in April 2013 that the FDA had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta during a single 12-month period. The group also reported that compared to other classes of diabetes drugs, incretin mimetics were far more likely to be associated with pancreatic cancer.*
Individuals treated with Byetta, Januvia, Victoza or other incretin mimetics may be entitled to compensation if they developed pancreatic cancer, pancreatitits, or thyroid cancer. To learn more about the litigation involving this class of diabetes drugs, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.
*ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com